metadata toggle
Pharmacological particulars
Pharmacotherapeutic group: antibacterials for systemic use, macrolides
ATC vet code: QJ01FA91.
Pharmacodynamic properties
Tilmicosin is a semi-synthetic antibiotic of the macrolide group, and is believed to affect protein synthesis. It has bacteriostatic action but at high concentrations it may be bactericidal. This antibacterial activity is predominantly against Gram-positive microorganism with activity against certain gram-negative ones and Mycoplasma of a bovine, porcine, ovine and avian origin. In particular its activity has been demonstrated against the following micro-organism:
Pigs: Mycoplasma hyopneumoniae, Pasteurella multocida, Actinobacillus pleuropneumoniae.
Rabbits: Pasteurella multocida, Staphylococcus aureus and Bordetella bronchoseptica
Scientific evidence suggests that macrolides act synergistically with the host immune system. Macrolides appear to enhance phagocyte killing of bacteria. Tilmicosin has been shown to inhibit in vitro the replication of the Porcine Reproductive and Respiratory Syndrome virus in alveolar macrophages in a dose dependent fashion.
Cross resistance between tilmicosin and other macrolides and lincomycin has been observed.
Pharmacokinetic particulars
Pigs:
Absorption: When administered to pigs via the oral route at a dose of 400 mg tilmicosin/kg feed (equivalent to approximately 21.3 mg tilmicosin/kg bodyweight/day), tilmicosin moves rapidly out of the serum into areas of low pH. The highest concentration in the serum (0.23±0.08 µg/ml) was recorded on day 10 of medication, but concentrations above the limit of quantification (0.10 µg/ml) were not found in 3 out of 20 animals examined. Lung concentrations increased rapidly between days 2 and 4 but no significant changes were obtained following four days of dosing. The maximum concentration in lung tissue (2.59±1.01 µg/ml) was recorded on day 10 of medication.
When administered at a dose of 200 mg tilmicosin/kg feed (equivalent to approximately 11.0 mg/kg/day), plasma concentrations above the limit of quantification (0.10 μg/ml) were found in 3 out of 20 animals examined. Quantifiable levels of tilmicosin were found in lung tissue with the maximum concentration (1.43±1.13 μg/ml) being recorded on day 10 of medication.
Distribution: Following oral administration, tilmicosin is distributed throughout the body with especially high levels found in the lung and in lung tissue macrophages. It is also distributed in the liver and kidney tissues.
Rabbits:
Absorption: When administered orally to rabbits at a dose of 12 mg tilmicosin/kg b.w. as a single dose there is a quick absorption. Maximum concentrations were reached in 30 minutes, being the Cmax obtained of 0.35 μg/ml. Tilmicosin plasma concentrations decreased to 0.1 μg/ml within 2 hours and to 0.02 μg/ml after 8 hours. The elimination half-life was 22 hours.
Distribution: Following oral administration, tilmicosin is distributed throughout the body with
especially high levels found in lungs. After 5 days of treatment with medicated feed at a dosage of 200 ppm of Pulmotil, tilmicosin concentrations in lung tissues were of 192 ± 103 μg/g.
Applicable to both species:
Biotransformation: Several metabolites are formed, the predominant one being identified as T1. However the bulk of tilmicosin is excreted unchanged.
Elimination: Following oral administration, tilmicosin is excreted mainly via the bile into the faeces, but a small proportion is excreted via the urine.
Environmental properties
The primary route of environmental exposure is from manure applied to agricultural land as fertilizer. Tilmicosin degrades/declines slowly in the soil. Therefore, to protect soil and ground water, pig manure not to be spread onto the grass land and when spread onto arable land plough to a depth of 30 cm. Environmental assessments have demonstrated that the use of Pulmotil Premix as indicated is not expected to have any impact on the environment.